In July 2025, the U.S. FDA approved Sephience, a novel oral drug that significantly increases phenylalanine hydroxylase (PAH) activity, lowering blood phenylalanine by ~63% in PKU patients and easing dietary restrictions. This evidence concerns the gene PAH and phenylketonuria.